Gary Lipshutz

Dr. Gary Lipshutz is a Professor at the University of California Los Angeles (UCLA), holding concurrent roles in multiple departments including Surgery, Urology, Molecular and Medical Pharmacology, Psychiatry and Biobehavioral Sciences, and Medicine. His work spans translational research, gene therapy, and metabolic disorders. He has led studies on enzyme deficiencies (e.g., CPS1, arginase), liver transplantation, and mRNA-based therapies. Key contributions include advancements in AAV vector engineering, PET imaging biomarkers, and clinical trials for genetic disorders like creatine transporter deficiency and propionic acidaemia.

Research Interests: Gene therapy, metabolic disease pathophysiology, enzyme replacement strategies, immunosuppressive approaches for viral vectors, and translational imaging. His interdisciplinary work bridges molecular pharmacology with clinical applications, addressing challenges in inherited metabolic disorders and organ transplantation.

Publications Trends: Recent work focuses on mRNA therapies, CRISPR applications, and biomarker development for CNS disorders. Collaborations emphasize multi-organ systems, particularly liver and brain interactions in metabolic diseases. He has published extensively in Molecular Therapy, Nature Communications, and Journal of Nuclear Medicine.

Advising/Grants: Advises on NIH T32 training grants and mentors trainees in gene therapy and metabolic research. His lab has received funding for studies on creatine transporter deficiency and AAV-based liver therapies.

Labs/Teams: Leads a multidisciplinary team at UCLA focused on translational therapies for metabolic and genetic disorders, collaborating with radiologists, immunologists, and clinical investigators across departments.